| scholarly article | Q13442814 |
| P2093 | author name string | Junbo Ge | |
| Xin Du | |||
| Ping Yang | |||
| Lu Bai | |||
| Jing Sun | |||
| Yang Zheng | |||
| Xianhong Wang | |||
| Shuren Ma | |||
| Chang-Sheng Ma | |||
| Xi Su | |||
| Maria Leonsson-Zachrisson | |||
| Zaixin Yu | |||
| YINGLONG study investigators | |||
| P2860 | cites work | [Chinese guideline for percutaneous coronary intervention(2016)] | Q89274980 |
| Ticagrelor versus clopidogrel in patients with acute coronary syndromes | Q29619002 | ||
| The evolving epidemiology of acute coronary syndromes | Q30397739 | ||
| Acute coronary syndromes: morbidity, mortality, and pharmacoeconomic burden. | Q33428261 | ||
| CYP2C19 phenotype, stent thrombosis, myocardial infarction, and mortality in patients with coronary stent placement in a Chinese population | Q34649009 | ||
| Variability in response to clopidogrel: how important are pharmacogenetics and drug interactions? | Q35373698 | ||
| Ticagrelor versus clopidogrel in Asian patients with acute coronary syndrome: A retrospective analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial | Q35647278 | ||
| Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist | Q37552005 | ||
| Genotyping-guided approach versus the conventional approach in selection of oral P2Y12 receptor blockers in Chinese patients suffering from acute coronary syndrome | Q38380508 | ||
| Rationale and design of the Improving Care for Cardiovascular Disease in China (CCC) project: A national effort to prompt quality enhancement for acute coronary syndrome | Q39421985 | ||
| Prospective observational study of acute coronary syndromes in China: practice patterns and outcomes | Q39817032 | ||
| Ticagrelor vs. clopidogrel in Japanese, Korean and Taiwanese patients with acute coronary syndrome -- randomized, double-blind, phase III PHILO study. | Q40533249 | ||
| Ticagrelor binds to human P2Y(12) independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation. | Q45954831 | ||
| Evidence-based medication use among Chinese patients with acute coronary syndromes at the time of hospital discharge and 1 year after hospitalization: results from the Clinical Pathways for Acute Coronary Syndromes in China (CPACS) study | Q46105962 | ||
| Characterization of the adenosine pharmacology of ticagrelor reveals therapeutically relevant inhibition of equilibrative nucleoside transporter 1. | Q46707933 | ||
| Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes | Q46916589 | ||
| 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. | Q49683918 | ||
| CYP2C19 polymorphisms in acute coronary syndrome patients undergoing clopidogrel therapy in Zhengzhou population. | Q51693029 | ||
| Safety and Incidence of Cardiovascular Events in Chinese Patients with Acute Coronary Syndrome Treated with Ticagrelor: the 12-Month, Phase IV, Multicenter, Single-Arm DAYU Study. | Q52682104 | ||
| P433 | issue | 7 | |
| P921 | main subject | acute coronary syndrome | Q266018 |
| P304 | page(s) | 1595-1605 | |
| P577 | publication date | 2019-05-22 | |
| P1433 | published in | Advances in Therapy | Q4686392 |
| P1476 | title | YINGLONG: A Multicenter, Prospective, Non-Interventional Study Evaluating the Safety and Tolerability of Ticagrelor in Chinese Patients with Acute Coronary Syndrome | |
| P478 | volume | 36 |
Search more.